Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25181350 | 0.91 | KLK5 (0.50) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL23834107 | 0.91 | KLK5 (0.50) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL20255053 | 0.87 | LTA4H (0.51) | HDAC1HDAC4HDAC8MAPTALDH1A1 | |
| SCHEMBL3503092 | 0.83 | HDAC1 (0.64) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL3503798 | 0.83 | HDAC1 (0.64) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL20253488 | 0.83 | LTA4H (0.55) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL14254911 | 0.82 | HDAC4 (0.65) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL23176824 | 0.81 | CTSK (0.58) | HDAC1HDAC4 | |
| SCHEMBL31407356 | 0.81 | ACE (0.56) | HDAC1HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL5129671 | 0.81 | CTSK (0.47) | HDAC1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795304-B2 | such as S)-[6-Hydroxycarbamoyl-1-(4-phenyl-thiazol-2-ylcarbamoyl)-hexyl]-carbamic acid benzyl ester, useful in the prevention and/or treatment cancer, restenosis, autoimmune diseases, allergies, inflammatory diseases, nervous system disorders such as neurodegenerative diseases | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7737184-B2 | Histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7534918-B2 | Histone deacetylase inhibitors | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118291-A1 | Histone deacetylase inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20080033015-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080015216-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-01-17 | — | — | US | disclosed |
| EP-1784386-A4 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO INC (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1784194-A1 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1784386-A2 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1773761-A1 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006026260-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017215-A2 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017216-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118291-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC4 5/4885HDAC8 7/4885 |
| US-20080015216-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC4 7/4885HDAC8 6/4885 |
| US-20080033015-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC4 4/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.